A novel hydrogen bonded bimetallic supramolecular coordination polymer {[SnMe3(bpe)][Ag(CN)2] · 2H2O} as anticancer drug.
The reaction of Me(3)SnCl, K(3)[Ag(CN)(4)] and 1,2-bis(4-pyridyl)ethane (bpe) in water/CH(3)CN solution at room temperature affords the novel bimetallic supramolecular coordination polymer (SCP) {[SnMe(3)(bpe)] [Ag(CN)2] · 2H(2)O}(n), 1. The structure of 1 consists of cationic {-Sn(Me(3))-bpe-}(+) chains that are neutralized by [Ag(CN)(2)](-) anions. The dicyanoargentate(I) anions present discrete uncoordinated fragments between the cationic chains. The water molecules bind the cationic chains and the anions forming 3D-supramolecular structure through hydrogen bonds. 1 exhibits strong fluorescence in the solid state at room temperature. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the in vitro antitumor effects of the SCP 1 on human breast cancer cell line, T-47D. Cell cycle analysis revealed that the SCP 1 induced apoptosis in T-47D breast cancer cell line. Moreover, in vivo, the SCP 1 showed tumor growth inhibition in rat model that developed mammary carcinoma by 44.8% compared to the vehicle treated control. Thus, the SCP 1 exhibits specific in vivo and in vitro antitumor effects.